Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
作者信息
Funck-Brentano Christian, Salem Joe-Elie, Nguyen Lee S, Drici Milou-Daniel, Roden Dan M
机构信息
Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France.
Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, INSERM, CIC Paris-Est (CIC-1901), Department of Pharmacology, 75013 Paris, France.
出版信息
Arch Cardiovasc Dis. 2020 May;113(5):367-368. doi: 10.1016/j.acvd.2020.04.001. Epub 2020 Apr 15.
Abstract
摘要
相似文献
1
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.对社论《心血管疾病患者的COVID-19》的回应：使用羟氯喹或氯喹及阿奇霉素治疗COVID-19：尖端扭转型室速的潜在风险。
Arch Cardiovasc Dis. 2020 May;113(5):367-368. doi: 10.1016/j.acvd.2020.04.001. Epub 2020 Apr 15.
2
QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.QT 间期延长、尖端扭转型室性心动过速和 COVID-19 短期使用氯喹或羟氯喹导致的猝死：系统评价。
Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008. Epub 2020 May 11.
3
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
4
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
5
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.COVID-19 患者接受羟氯喹/阿奇霉素治疗后出现 QT 间期延长和尖端扭转型室性心动过速。
Heart Rhythm. 2020 Sep;17(9):1425-1433. doi: 10.1016/j.hrthm.2020.05.014. Epub 2020 May 12.
6
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.1例2019冠状病毒病患者出现氯喹诱导的尖端扭转型室速
Heart Rhythm. 2020 Sep;17(9):1452-1455. doi: 10.1016/j.hrthm.2020.04.046. Epub 2020 May 5.
7
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
8
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
9
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.与阿奇霉素联合或不联合氯喹或羟氯喹相关的QT间期延长或尖端扭转型室速的安全信号。
Res Social Adm Pharm. 2021 Feb;17(2):483-486. doi: 10.1016/j.sapharm.2020.04.016. Epub 2020 Apr 19.
10
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.探索性新冠肺炎治疗中药物相互作用对QTc的影响因素
Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.
引用本文的文献
1
Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.阿奇霉素的年龄分层药物警戒：FAERS数据库中的多方法信号检测分析
J Pharm Policy Pract. 2025 Jul 8;18(1):2525356. doi: 10.1080/20523211.2025.2525356. eCollection 2025.
2
A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.关于间充质干细胞及其分泌组在对抗 COVID-19 患者病死率和发病率方面的潜在应用的简要综述。
Biomed J. 2021 Mar;44(1):63-73. doi: 10.1016/j.bj.2020.09.003. Epub 2020 Sep 28.
3
Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.治疗 SARS-CoV-2 的药物：现状和展望。
Int Immunopharmacol. 2021 Jan;90:107228. doi: 10.1016/j.intimp.2020.107228. Epub 2020 Nov 27.
4
Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.洛匹那韦/利托那韦引起的 COVID-19 相关自发性心脏毒性反应。一个据称已经解决的旧问题。
Int J Cardiol. 2021 Feb 1;324:255-260. doi: 10.1016/j.ijcard.2020.10.028. Epub 2020 Oct 16.
5
Special features of SARS-CoV-2 in daily practice.严重急性呼吸综合征冠状病毒2在日常临床实践中的特点。
World J Clin Cases. 2020 Sep 26;8(18):3920-3933. doi: 10.12998/wjcc.v8.i18.3920.
6
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic.羟氯喹在 COVID-19 流行前和流行期间致心脏毒性的证据分析。
Clin Transl Sci. 2021 Jan;14(1):163-169. doi: 10.1111/cts.12883. Epub 2020 Oct 23.
7
Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.基于配体的虚拟筛选和小分子盲对接揭示了 SARS-CoV-2 主蛋白酶二聚体界面上的一个可能的靶位。
Comput Biol Chem. 2020 Dec;89:107372. doi: 10.1016/j.compbiolchem.2020.107372. Epub 2020 Sep 5.
8
Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19.撤稿与重新发表：羟氯喹在2019冠状病毒病中的心脏毒性
Lancet. 2020 Jul 18;396(10245):e2-e3. doi: 10.1016/S0140-6736(20)31528-2. Epub 2020 Jul 9.
9
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.羟氯喹啉和阿奇霉素相关的心血管毒性：世界卫生组织药物警戒数据库分析
Circulation. 2020 Jul 21;142(3):303-305. doi: 10.1161/CIRCULATIONAHA.120.048238. Epub 2020 May 22.
10
"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.羟氯喹、阿奇霉素、洛匹那韦-利托那韦和氯喹在 COVID-19 中的“超适应证”使用：法国药物警戒中心网络对心脏不良药物反应的调查。
Therapie. 2020 Jul-Aug;75(4):371-379. doi: 10.1016/j.therap.2020.05.002. Epub 2020 May 7.
本文引用的文献
1
COVID-19 in patients with cardiovascular diseases.心血管疾病患者中的新型冠状病毒肺炎
Arch Cardiovasc Dis. 2020 Apr;113(4):225-226. doi: 10.1016/j.acvd.2020.03.009. Epub 2020 Mar 31.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation.白细胞介素-6 抑制 hERG 是心脏和全身炎症中获得性长 QT 风险的基础。
PLoS One. 2018 Dec 6;13(12):e0208321. doi: 10.1371/journal.pone.0208321. eCollection 2018.
4
Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.评估多离子通道阻滞：I 期随机研究设计的结果：CiPA I 期心电图生物标志物验证研究。
Clin Pharmacol Ther. 2019 Apr;105(4):943-953. doi: 10.1002/cpt.1303. Epub 2019 Jan 18.
5
Azithromycin Causes a Novel Proarrhythmic Syndrome.阿奇霉素会引发一种新型的心律失常综合征。
Circ Arrhythm Electrophysiol. 2017 Apr;10(4). doi: 10.1161/CIRCEP.115.003560.
6
Assessment of temperature-induced hERG channel blockade variation by drugs.药物对温度诱导的人乙醚相关基因（hERG）通道阻滞变化的评估。
J Appl Toxicol. 2015 Jul;35(7):799-805. doi: 10.1002/jat.3074. Epub 2014 Oct 28.
7
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.二氢青蒿素-哌喹复方制剂与其他抗疟药的体外心血管效应比较。
Antimicrob Agents Chemother. 2012 Jun;56(6):3261-70. doi: 10.1128/AAC.05688-11. Epub 2012 Mar 5.
8
Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.长期使用羟氯喹与QT间期延长及难治性室性心律失常相关。
Clin Toxicol (Phila). 2006;44(2):173-5. doi: 10.1080/15563650500514558.
Zotero 插件